drugset / Trial / NCT07087327

A Long-term Trial of EB-1020 in Pediatric Patients With ADHD

NCT07087327

Phase 3 Recruiting 180 enrolled Otsuka Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients.

Timeline

Start
2025-09-16
Primary completion
2027-08
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Centanafadine Small molecule Oral